Barclay Robert A, Schwab Angela, DeMarino Catherine, Akpamagbo Yao, Lepene Benjamin, Kassaye Seble, Iordanskiy Sergey, Kashanchi Fatah
Laboratory of Molecular Virology, George Mason University, Manassas, Virginia 20110.
Ceres Nanosciences Inc., Manassas, Virginia 20110.
J Biol Chem. 2017 Jul 14;292(28):11682-11701. doi: 10.1074/jbc.M117.793521. Epub 2017 May 23.
HIV-1 infection causes AIDS, infecting millions worldwide. The virus can persist in a state of chronic infection due to its ability to become latent. We have previously shown a link between HIV-1 infection and exosome production. Specifically, we have reported that exosomes transport viral proteins and RNA from infected cells to neighboring uninfected cells. These viral products could then elicit an innate immune response, leading to activation of the Toll-like receptor and NF-κB pathways. In this study, we asked whether exosomes from uninfected cells could activate latent HIV-1 in infected cells. We observed that irrespective of combination antiretroviral therapy, both short- and long-length viral transcripts were increased in wild-type HIV-1-infected cells exposed to purified exosomes from uninfected cells. A search for a possible mechanism for this finding revealed that the exosomes increase RNA polymerase II loading onto the HIV-1 promoter in the infected cells. These viral transcripts, which include trans-activation response (TAR) RNA and a novel RNA that we termed TAR-, can then be packaged into exosomes and potentially be exported to neighboring uninfected cells, leading to increased cellular activation. To better decipher the exosome release pathways involved, we used siRNA to suppress expression of ESCRT (endosomal sorting complex required for transport) proteins and found that ESCRT II and IV significantly control exosome release. Collectively, these results imply that exosomes from uninfected cells activate latent HIV-1 in infected cells and that true transcriptional latency may not be possible , especially in the presence of combination antiretroviral therapy.
HIV-1感染会导致艾滋病,全球数百万人受到感染。由于该病毒具有潜伏的能力,它可以持续处于慢性感染状态。我们之前已经证明了HIV-1感染与外泌体产生之间的联系。具体而言,我们报道过外泌体将病毒蛋白和RNA从感染细胞转运到邻近的未感染细胞。这些病毒产物随后可引发先天免疫反应,导致Toll样受体和NF-κB信号通路的激活。在本研究中,我们探究了未感染细胞产生的外泌体是否能激活感染细胞中的潜伏HIV-1。我们观察到,无论联合抗逆转录病毒疗法如何,暴露于来自未感染细胞的纯化外泌体的野生型HIV-1感染细胞中,短长度和长长度的病毒转录本均增加。对这一发现的可能机制进行探索后发现,外泌体增加了感染细胞中RNA聚合酶II在HIV-1启动子上的负载。这些病毒转录本,包括反式激活应答(TAR)RNA和一种我们称为TAR-的新型RNA,随后可被包装到外泌体中,并有可能被转运到邻近的未感染细胞,导致细胞激活增加。为了更好地解读所涉及的外泌体释放途径,我们使用小干扰RNA(siRNA)抑制转运所需内体分选复合物(ESCRT)蛋白的表达,发现ESCRT II和IV显著控制外泌体释放。总体而言,这些结果表明,未感染细胞产生的外泌体可激活感染细胞中的潜伏HIV-1,并且真正的转录潜伏期可能不存在,尤其是在联合抗逆转录病毒疗法存在的情况下。